

**Study Number:** C20299  
**Test Type:** TOX  
**Route:** Oral Gavage  
**Species/Strain:** Rat/Harlan Sprague Dawley

**PA41: Clinical Chemistry Summary**  
**Test Compound:** Isodecyl Diphenyl Phosphate  
**CAS Number:** 29761-21-5

**Date Report Requested:** 08/24/2021  
**Time Report Requested:** 10:55:04  
**Lab:** NTP

**Study Number:** C20299  
**Study Gender:** Male  
**PWG Approval Date:** See web page for date of PWG Approval  
**Version:** v1.3.0  
**Stat Version:** v2.6.3A

Study Number: C20299

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary  
Test Compound: Isodecyl Diphenyl Phosphate  
CAS Number: 29761-21-5

Date Report Requested: 08/24/2021

Time Report Requested: 10:55:04

Lab: NTP

Male

	Phase Day	Treatment Groups (mMol/kg)				
		0	0.169	0.338	0.675	1.35
Urea Nitrogen (mg/dL)	SD 4	12.0 ± 0.8 (5)	11.0 ± 0.5 (5)	11.6 ± 1.0 (5)	13.0 ± 0.7 (5)	10.4 ± 0.9 (5)
Percent of Control			91.7	96.7	108.3	86.7
Creatinine (mg/dL)	SD 4	0.29 ± 0.01 (5)	0.28 ± 0.01 (5)	0.27 ± 0.01 (5)	0.28 ± 0.01 (5)	0.26 ± 0.01 (5)
Percent of Control			96.5	94.4	95.8	91.0
Total Protein (g/dL)	SD 4	5.94 ± 0.13 (5)	5.88 ± 0.12 (5)	6.02 ± 0.06 (5)	5.90 ± 0.14 (5)	6.10 ± 0.09 (5)
Percent of Control			99.0	101.3	99.3	102.7
Globulin (g/dL)	SD 4	2.50 ± 0.07 (5) **	2.44 ± 0.07 (5)	2.58 ± 0.04 (5)	2.56 ± 0.07 (5)	2.72 ± 0.04 (5)
Percent of Control			97.6	103.2	102.4	108.8
A/G Ratio	SD 4	1.38 ± 0.03 (5) **	1.41 ± 0.03 (5)	1.33 ± 0.02 (5)	1.31 ± 0.02 (5)	1.24 ± 0.01 (5) **
Percent of Control			102.5	96.8	94.7	90.1
Albumin (g/dL)	SD 4	3.44 ± 0.07 (5)	3.44 ± 0.06 (5)	3.44 ± 0.04 (5)	3.34 ± 0.07 (5)	3.38 ± 0.06 (5)
Percent of Control			100.0	100.0	97.1	98.3
Cholesterol (mg/dL)	SD 4	101.0 ± 5.8 (5) **	105.6 ± 4.6 (5)	111.2 ± 6.2 (5)	122.2 ± 3.6 (5) *	142.2 ± 2.5 (5) **
Percent of Control			104.6	110.1	121.0	140.8
Triglyceride (mg/dL)	SD 4	54.0 ± 6.0 (5)	52.8 ± 7.9 (5)	53.0 ± 6.6 (5)	54.8 ± 4.6 (5)	52.6 ± 2.2 (5)
Percent of Control			97.8	98.1	101.5	97.4
LDL Cholesterol (mg/dL)	SD 4	21.8 ± 0.7 (5)	23.0 ± 1.1 (5)	24.2 ± 1.0 (5)	23.8 ± 1.1 (5)	24.4 ± 0.7 (5)
Percent of Control			105.5	111.0	109.2	111.9
HDL Cholesterol (mg/dL)	SD 4	46.0 ± 2.9 (5) **	50.0 ± 2.3 (5)	51.8 ± 2.5 (5)	54.0 ± 1.9 (5) *	64.8 ± 1.7 (5) **
Percent of Control			108.7	112.6	117.4	140.9
Alanine Aminotransferase (IU/L)	SD 4	61.4 ± 4.5 (5)	71.6 ± 6.0 (5)	63.0 ± 3.8 (5)	85.2 ± 12.4 (5)	61.4 ± 2.6 (5)
Percent of Control			116.6	102.6	138.8	100.0

Study Number: C20299

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary  
Test Compound: Isodecyl Diphenyl Phosphate  
CAS Number: 29761-21-5

Date Report Requested: 08/24/2021

Time Report Requested: 10:55:04

Lab: NTP

---

Male

---

	Phase Day	Treatment Groups (mMol/kg)				
		0	0.169	0.338	0.675	1.35
Aspartate Aminotransferase (U/L) Percent of Control	SD 4	107.40 ± 10.21 (5)	105.40 ± 10.47 (5) 98.1	84.20 ± 3.76 (5) 78.4	107.20 ± 17.94 (5) 99.8	81.20 ± 8.77 (5) 75.6
Sorbitol Dehydrogenase (IU/L) Percent of Control	SD 4	10.4 ± 0.7 (5)	10.2 ± 0.7 (5) 97.9	9.7 ± 0.8 (5) 92.7	15.8 ± 3.3 (5) 151.8	10.8 ± 0.9 (5) 103.8
Bile salt/acids (umol/L) Percent of Control	SD 4	57.4 ± 8.8 (5) **	53.9 ± 4.1 (5) 93.8	34.5 ± 4.3 (5) 60.0	40.8 ± 6.3 (5) 71.0	32.3 ± 5.6 (5) * 56.3

**Study Number:** C20299

**Test Type:** TOX

**Route:** Oral Gavage

**Species/Strain:** Rat/Harlan Sprague Dawley

**PA41: Clinical Chemistry Summary**  
**Test Compound:** Isodecyl Diphenyl Phosphate  
**CAS Number:** 29761-21-5

**Date Report Requested:** 08/24/2021

**Time Report Requested:** 10:55:04

**Lab:** NTP

---

**Male**

---

	<b>Phase Day</b>	<b>Treatment Groups</b>
		<b>2.7</b>
Urea Nitrogen (mg/dL)	SD 4	12.2 ± 0.9 (5)
Percent of Control		101.7
Creatinine (mg/dL)	SD 4	0.29 ± 0.01 (5)
Percent of Control		100.0
Total Protein (g/dL)	SD 4	6.06 ± 0.14 (5)
Percent of Control		102.0
Globulin (g/dL)	SD 4	2.66 ± 0.09 (5)
Percent of Control		106.4
A/G Ratio	SD 4	1.28 ± 0.03 (5) *
Percent of Control		93.0
Albumin (g/dL)	SD 4	3.40 ± 0.05 (5)
Percent of Control		98.8
Cholesterol (mg/dL)	SD 4	146.4 ± 6.5 (5) **
Percent of Control		145.0
Triglyceride (mg/dL)	SD 4	42.2 ± 3.6 (5)
Percent of Control		78.1
LDL Cholesterol (mg/dL)	SD 4	22.8 ± 0.5 (5)
Percent of Control		104.6
HDL Cholesterol (mg/dL)	SD 4	69.8 ± 4.2 (5) **
Percent of Control		151.7
Alanine Aminotransferase (IU/L)	SD 4	69.2 ± 2.3 (5)
Percent of Control		112.7

**Study Number:** C20299

**Test Type:** TOX

**Route:** Oral Gavage

**Species/Strain:** Rat/Harlan Sprague Dawley

**PA41: Clinical Chemistry Summary**

**Test Compound:** Isodecyl Diphenyl Phosphate

**CAS Number:** 29761-21-5

**Date Report Requested:** 08/24/2021

**Time Report Requested:** 10:55:04

**Lab:** NTP

---

**Male**

---

	<b>Phase Day</b>	<b>Treatment Groups</b>
		<b>2.7</b>
Aspartate Aminotransferase (U/L)	SD 4	89.00 ± 4.89 (5)
Percent of Control		82.9
Sorbitol Dehydrogenase (IU/L)	SD 4	10.7 ± 0.8 (5)
Percent of Control		102.9
Bile salt/acids (umol/L)	SD 4	32.1 ± 4.3 (5) *
Percent of Control		56.0

**Study Number:** C20299

**Test Type:** TOX

**Route:** Oral Gavage

**Species/Strain:** Rat/Harlan Sprague Dawley

**PA41: Clinical Chemistry Summary**

**Test Compound:** Isodecyl Diphenyl Phosphate

**CAS Number:** 29761-21-5

**Date Report Requested:** 08/24/2021

**Time Report Requested:** 10:55:04

**Lab:** NTP

## LEGEND

---

Values given as mean  $\pm$  SEM (N) with Percent of Control calculated by (dosed group mean / control group mean) x 100

SD – Study Day

Statistical analysis was performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

\* Statistically significant at  $P \leq 0.05$

\*\* Statistically significant at  $P \leq 0.01$

**\*\* END OF REPORT \*\***